Pfizer has agreed to sell its 11.7% stake in GSK’s ViiV Healthcare for nearly $1.9 billion, marking a strategic move amid projected revenue declines for 2026. Under the agreement, Shionogi will acquire Pfizer’s shares for $2.125 billion, increasing its stake in the HIV-focused company from 10% to 21.7%. In addition, GSK will receive a special dividend of $250 million as part of the transaction.
The deal maintains GSK’s majority control with a 78.3% interest in ViiV and is expected to close in the first quarter of 2026, simplifying the shareholder structure and strengthening collaboration between ViiV and Shionogi.
Strategic Implications for the HIV Treatment Market
Since its launch in 2009, ViiV Healthcare has focused on HIV treatment and prevention, providing innovative medicines and resources to support people living with AIDS. Originally, GSK held an 85% stake and Pfizer 15%. Shionogi joined in 2012, contributing its HIV portfolio in exchange for royalties and a 10% stake.
The sale of Pfizer’s stake allows Shionogi to deepen its involvement in ViiV’s pipeline, which includes long-acting injectable therapies such as dolutegravir and cabotegravir, integrase inhibitors that have redefined HIV care.
“Shionogi is dedicated to addressing major infectious diseases, with HIV being one of our most important focus areas,” said John Keller, Ph.D., Chief of R&D at Shionogi.
ViiV Performance and Market Context
ViiV Healthcare reported HIV treatment sales of £7.1 billion ($9.1 billion) in 2024, trailing Gilead Sciences, whose HIV portfolio generated $19.6 billion. This reflects strong growth since ViiV’s inception, when GSK’s HIV products earned £1.6 billion ($2.1 billion) in 2008.
The transaction positions ViiV for continued innovation in HIV therapeutics, with simplified ownership expected to accelerate strategic decision-making and clinical development.
Pfizer’s Financial Context
Pfizer announced a projected 2026 revenue of $59.5–$62.5 billion, a decline from 2024 and 2025 figures. This reflects a $1.5 billion drop in COVID product sales and a $1.5 billion impact from loss of exclusivity (LOE) for several drugs. LOE challenges are expected to escalate, reaching $3 billion+ in 2027 and $6 billion+ in 2028, with growth anticipated only by 2029.
Selling its ViiV stake provides Pfizer with liquidity and financial flexibility while enabling Shionogi to expand in the HIV market.
Looking Ahead: HIV Treatment and Strategic Partnerships
The agreement underscores the importance of strategic partnerships in the pharmaceutical industry, particularly in specialized areas like HIV. ViiV’s pipeline of long-acting injectable HIV therapies is a market differentiator, and Shionogi’s increased stake reinforces its commitment to advancing global HIV care.
“We look forward to continuing our highly successful collaboration with Shionogi to advance ViiV’s portfolio of HIV treatment and prevention medicines,” said David Redfern, Chairman of ViiV Healthcare.
Sources and References
- ViiV Healthcare Official Announcement
- Pfizer Investor News
- GSK ViiV Healthcare Information
- Shionogi Press Release
- Financial Times – Pfizer Sells Stake in ViiV
FAQ – Pharmaceutical Professionals
Q1: Why did Pfizer sell its stake in ViiV?
A: Pfizer sold its 11.7% stake for $1.875B to gain liquidity amid projected revenue declines and loss of exclusivity for key products.
Q2: How does this affect Shionogi’s role?
A: Shionogi increases its stake to 21.7%, strengthening its influence on ViiV’s HIV treatment pipeline and maintaining a board director position.
Q3: What are the key HIV medicines in ViiV’s portfolio?
A: ViiV focuses on long-acting injectable integrase inhibitors, including dolutegravir and cabotegravir, designed for both treatment and prevention.
Q4: What is the market impact of this deal?
A: It simplifies ViiV’s ownership structure, accelerates strategic decision-making, and strengthens collaborations in HIV therapy innovation.
Q5: How will Pfizer’s 2026 revenue be impacted?
A: The sale offsets revenue declines from COVID products and loss of exclusivity, providing short-term funding while growth is expected only by 2029.
